Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Monsanto Co. -- Ignore unavailable to you. Want to Upgrade?

To: John F Beule who wrote (886)	1/15/1999 4:26:00 PM
From: jopawa	Read Replies (3) \| Respond to of 2539

Bad news on the drug front. Friday January 15, 4:01 pm Eastern Time (Note: this article is ''in progress''; there will likely be an update soon.) Monsanto halts studies on two heart drugs SKOKIE, Ill., Jan 15 (Reuters) - Life sciences firm Monsanto Co. (NYSE:MTC - news) said Friday its Searle pharmaceutical unit halted studies on two anti-clotting drugs that the company had hoped would reduce the risk of repeat heart attacks. Searle said that after analyzing data from Phase III clinical trials it found the drugs orbofiban and xemilofiban did not demonstrate significant clinical benefit in reducing the number of deaths, repeat heart attacks and certain other problems. In November, Searle stopped taking new patients for one orbofiban study after an unexplained rise in deaths among one group of participants in the trial.